Hypersensitivity to CGRP as a Predictive Biomarker of Migraine Prevention With Erenumab
Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
To explore the relationship between clinical response to erenumab and response to intravenous
infusion of calcitonin gene-related peptide in individuals with migraine.